

Table 1.22
U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2015^a
Using Different Tumor Inclusion Criteria^b

Site	Sex	5-Year Limited Duration			40-year Limited Duration	
		1st Invasive Tumor Ever ^c	1st Per Site in Previous 40 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 40 Years ^d
All Sites	Both Sexes	4,722,844	4,824,176	5,364,403	14,564,667	14,803,473
	Male	2,336,741	2,376,359	2,637,853	6,886,073	6,969,613
	Female	2,386,103	2,447,817	2,726,550	7,678,594	7,833,860
Oral Cavity & Pharynx	Both Sexes	119,650	140,282	146,087	315,830	351,683
	Male	85,201	99,042	102,445	213,376	235,817
	Female	34,449	41,240	43,642	102,454	115,866
Esophagus	Both Sexes	22,718	28,397	28,552	39,725	47,178
	Male	17,684	22,100	22,194	30,875	36,584
	Female	5,034	6,297	6,358	8,850	10,594
Stomach	Both Sexes	40,050	48,431	49,134	83,535	96,852
	Male	23,823	29,145	29,511	47,851	55,915
	Female	16,227	19,286	19,623	35,684	40,937
Colon & Rectum	Both Sexes	388,393	447,554	457,029	1,184,519	1,317,472
	Male	200,410	230,711	235,400	592,981	656,924
	Female	187,983	216,843	221,629	591,538	660,548
Liver & Intrahepatic Bile Duct	Both Sexes	43,476	50,595	50,790	62,989	71,436
	Male	32,091	36,509	36,632	45,370	50,472
	Female	11,385	14,086	14,158	17,619	20,964
Pancreas	Both Sexes	41,541	51,213	51,287	56,595	68,335
	Male	21,365	26,612	26,669	28,337	34,642
	Female	20,176	24,601	24,618	28,258	33,693
Larynx	Both Sexes	31,888	37,523	38,098	87,909	98,750
	Male	25,677	30,180	30,662	70,763	79,299
	Female	6,211	7,343	7,436	17,146	19,451
Lung & Bronchus	Both Sexes	241,884	314,788	327,383	427,053	534,600
	Male	107,976	143,225	148,287	186,018	235,174
	Female	133,908	171,563	179,096	241,035	299,426
Melanoma of the Skin	Both Sexes	311,301	357,482	378,631	1,093,856	1,188,494
	Male	169,064	198,951	212,770	546,187	602,574
	Female	142,237	158,531	165,861	547,669	585,920
Breast	Female	919,418	1,000,641	1,067,300	3,186,386	3,383,211
Cervix	Female	39,276	41,471	41,584	222,360	228,508
Corpus & Uterus, NOS	Female	199,512	224,764	224,949	648,910	711,315
Ovary ^f	Female	61,387	70,296	70,355	188,419	211,175

^a U.S. 2015 cancer prevalence counts are based on 2015 cancer prevalence proportions from the SEER 9 registries and 1/1/2015 U.S. population estimates based on the average of 2014 and 2015 population estimates from the U.S. Bureau of the Census.

^b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

^c (c) First invasive tumor ever

^d (d) First invasive tumor for each cancer site diagnosed during the previous 40 years (1975-2014)

^e (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2010-2014)

For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2010; Melanoma in 2011.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 40-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2015.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 40-year limited duration prevalence. The 2010 breast cancer is counted for the breast 5-year and 40-year limited duration prevalence.

In method (e) the 2010 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2011 melanoma is counted for 5-year limited duration prevalence for melanoma.

^f Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table 1.22 - continued
 U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2015^a
 Using Different Tumor Inclusion Criteria^b

Site	Sex	5-Year Limited Duration			40-year Limited Duration	
		1st Invasive Tumor Ever ^c	1st Per Site in Previous 40 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 40 Years ^d
Prostate	Male	904,841	981,660	981,708	2,930,034	3,119,586
Testis	Male	43,676	44,722	45,419	240,638	244,108
Urinary Bladder	Both Sexes	209,289	264,140	270,460	595,422	699,906
	Male	159,522	202,342	207,410	444,468	523,805
	Female	49,767	61,798	63,050	150,954	176,101
Kidney & Renal Pelvis	Both Sexes	164,860	202,123	205,347	421,973	494,409
	Male	103,366	127,961	130,183	254,134	300,381
	Female	61,494	74,162	75,164	167,839	194,028
Brain & Nervous System	Both Sexes	46,283	49,632	50,142	148,219	153,481
	Male	25,950	27,706	28,005	79,027	81,695
	Female	20,333	21,926	22,137	69,192	71,786
Thyroid	Both Sexes	206,116	231,486	232,345	673,927	726,654
	Male	46,591	55,337	55,526	145,745	161,902
	Female	159,525	176,149	176,819	528,182	564,752
Hodgkin Lymphoma	Both Sexes	37,408	39,654	39,732	190,947	196,508
	Male	20,709	22,013	22,057	99,255	102,171
	Female	16,699	17,641	17,675	91,692	94,337
Non-Hodgkin Lymphoma	Both Sexes	212,016	250,895	256,180	603,480	678,222
	Male	114,846	137,105	139,836	319,682	360,297
	Female	97,170	113,790	116,344	283,798	317,925
Myeloma	Both Sexes	64,947	76,977	77,405	107,880	124,483
	Male	35,484	43,060	43,330	58,762	68,975
	Female	29,463	33,917	34,075	49,118	55,508
Leukemia	Both Sexes	132,739	156,843	157,533	359,582	399,967
	Male	77,006	91,685	92,061	204,125	228,132
	Female	55,733	65,158	65,472	155,457	171,835
Acute Lymphocytic Leukemia	Both Sexes	17,562	18,283	18,283	80,053	81,139
	Male	9,392	9,771	9,771	43,576	44,099
	Female	8,170	8,512	8,512	36,477	37,040
Childhood (Ages 0-19)	Both Sexes	67,139	67,259	67,807	360,164	360,164
	Male	34,528	34,605	34,868	184,580	184,580
	Female	32,611	32,654	32,939	175,584	175,584
Kaposi Sarcoma	Both Sexes	7,206	7,837	7,837	28,593	30,123
	Male	6,671	7,226	7,226	27,086	28,436
	Female	535	611	611	1,507	1,687
Mesothelioma	Both Sexes	3,059	4,067	4,079	4,861	5,982
	Male	2,126	2,837	2,837	2,904	3,671
	Female	933	1,230	1,242	1,957	2,311

^a U.S. 2015 cancer prevalence counts are based on 2015 cancer prevalence proportions from the SEER 9 registries and 1/1/2015 U.S. population estimates based on the average of 2014 and 2015 population estimates from the U.S. Bureau of the Census.

^b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

^c (c) First invasive tumor ever

^d (d) First invasive tumor for each cancer site diagnosed during the previous 40 years (1975-2014)

^e (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2010-2014)

For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2010; Melanoma in 2011.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 40-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2015.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 40-year limited duration prevalence. The 2010 breast cancer is counted for the breast 5-year and 40-year limited duration prevalence.

In method (e) the 2010 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2011 melanoma is counted for 5-year limited duration prevalence for melanoma.